Mereo BioPharma’s share price is trading near the low end of its 52-week range after steep 1–6 month declines, with momentum indicators pointing to a market under pressure. Technical signals show persistent downside trend well below key moving averages and within a bearish Keltner and Ichimoku configuration, while short interest and short volume are elevated enough to indicate notable skepticism. The lack of disclosed financial fundamentals in the available data and a predominantly negative recent news backdrop related to legal investigations further underscores a cautious risk profile.